Athyrium Capital Management

Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

Vita Health operates an online mental health care platform focused on providing high-quality treatment for adolescents and transitional age youth. The platform enables patients to receive quick and accessible care from licensed therapists through telehealth services. It addresses various mental health challenges, including anxiety, depression, and suicidal ideation, ensuring that young individuals can conveniently access the support they need from the comfort of their homes.

Calliditas Therapeutics AB, headquartered in Stockholm, Sweden, is a specialty pharmaceutical company dedicated to developing high-quality medicines for patients with significant unmet medical needs in niche indications. The company focuses on the development and commercialization of Nefecon (also known as TARPEYO), a unique formulation designed to treat IgA nephropathy (IgAN), an inflammatory renal disease. This patented, locally acting formulation combines a time lag effect with a concentrated release of budesonide within a designated target area. Calliditas is conducting a global Phase 3 study for Nefecon and aims to commercialize it in the United States.

Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative treatments for severe bacterial and fungal infections, as well as oncology. The company markets isavuconazole, an antifungal drug available in intravenous and oral forms, to treat invasive aspergillosis and mucormycosis. Additionally, Basilea offers ceftobiprole, an intravenous antibiotic for treating community and hospital-acquired pneumonia, and is conducting Phase III clinical trials for its use in acute bacterial skin and skin structure infections, as well as Staphylococcus aureus bacteremia. The company is also advancing several investigational therapies, including Derazantinib, a small molecule inhibitor for intrahepatic cholangiocarcinoma; BAL101553, a tumor checkpoint controller; and BAL3833, a panRAF/SRC kinase inhibitor. With operational subsidiaries in the United Kingdom and Germany, Basilea Pharmaceutica's products are available in multiple countries, including the United States and various European and non-European markets.

uMotif Limited is a company specializing in data capture solutions for the healthcare industry. Established in 2012 and based in London, the company operates a patient-centered data capture platform that facilitates modern clinical research. uMotif’s application enables the capture and validation of various types of patient-generated data, including electronic consent, electronic clinical outcome assessments (eCOA), electronic patient-reported outcomes (ePRO), patient-reported outcome measures (PROM), and patient-reported experience measures (PREM). This technology serves a diverse range of clients, including pharmaceutical companies, medical device firms, biotechnology companies, contract research organizations (CROs), and academic institutions. By providing tools that enhance data collection, uMotif allows researchers and clinicians to gather rich health data across multiple conditions, ultimately supporting advancements in clinical research and patient care.

Revance Therapeutics, Inc. is a biotechnology company that specializes in the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic indications. The company's lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various stages of clinical trials for treatments including glabellar lines, cervical dystonia, adult upper limb spasticity, plantar fasciitis, and chronic migraine. Revance is also advancing DAXI for aesthetic applications such as forehead lines and lateral canthal lines. Additionally, the company is developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic uses, alongside a biosimilar formulation akin to BOTOX. Revance has established collaboration agreements for the development and commercialization of its biosimilar products. Founded in 1999 and headquartered in Newark, California, Revance was previously known as Essentia Biosystems, Inc., having rebranded in 2005. The company is committed to enhancing its portfolio in dermatology and aesthetic medicine, including a range of dermal fillers and a platform for aesthetic services.

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative products aimed at improving cancer care. Founded in 2010 and headquartered in Los Angeles, California, the company primarily focuses on the treatment of various forms of cancer, particularly through its lead product, NERLYNX, an oral formulation of neratinib designed for HER2-positive breast cancer patients. Additionally, Puma is developing PB357, an irreversible tyrosine kinase inhibitor that targets the epidermal growth factor receptors HER1, HER2, and HER4. The company operates under a licensing agreement with Pfizer for the development and commercialization of its drug candidates, including oral and intravenous forms of neratinib, as well as PB357. With a commitment to enhancing treatment outcomes, Puma Biotechnology is focused on advancing its clinical programs and bringing effective therapies to market for cancer patients.

Osmotica Pharmaceuticals plc is an integrated biopharmaceutical company headquartered in Bridgewater, New Jersey, specializing in the development and commercialization of pharmaceutical products primarily in the United States, Argentina, and Hungary. The company offers a diverse portfolio of products, including M-72, an extended-release tablet for attention deficit hyperactivity disorder (ADHD), and Osmolex ER, an extended-release tablet for Parkinson's disease and drug-induced extrapyramidal reactions. Other significant offerings include Lorzone for muscle spasms, ConZip for pain management, and Arbaclofen, which is currently in phase III clinical trials for multiple sclerosis spasticity. Osmotica also focuses on women's health with products like Divigel for menopause and OB Complete for prenatal care, alongside various other branded and generic medications targeting conditions such as hypertension and overactive bladder. The company employs its proprietary osmotic technology platform to enhance the efficacy of its pharmaceutical products, maintaining operations that include manufacturing facilities in the United States and Spain.

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative products aimed at improving cancer care. Founded in 2010 and headquartered in Los Angeles, California, the company primarily focuses on the treatment of various forms of cancer, particularly through its lead product, NERLYNX, an oral formulation of neratinib designed for HER2-positive breast cancer patients. Additionally, Puma is developing PB357, an irreversible tyrosine kinase inhibitor that targets the epidermal growth factor receptors HER1, HER2, and HER4. The company operates under a licensing agreement with Pfizer for the development and commercialization of its drug candidates, including oral and intravenous forms of neratinib, as well as PB357. With a commitment to enhancing treatment outcomes, Puma Biotechnology is focused on advancing its clinical programs and bringing effective therapies to market for cancer patients.

Amryt Pharma is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for patients with serious and life-threatening rare diseases. Founded in 2015 and based in London, the company offers several commercial products, including Myalept, which treats complications related to leptin deficiency in patients with generalized lipodystrophy, and Lojuxta, a medication for adults with homozygous familial hypercholesterolemia. Amryt Pharma is also advancing its research pipeline, including FILSUVEZ, aimed at treating the skin manifestations of epidermolysis bullosa, and AP103, a pre-clinical gene therapy for recessive dystrophic epidermolysis bullosa. The company markets its products across the Americas, Europe, and the Middle East, focusing on addressing high unmet medical needs in rare and orphan diseases.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel oral and small-molecule medicines to address rare diseases with significant unmet medical needs. The company's first approved product, RAPIVAB, is an intravenous neuraminidase inhibitor for treating acute uncomplicated influenza, marketed under various names globally. BioCryst has developed ORLADEYO, an oral medication approved for preventing hereditary angioedema attacks in adults and pediatric patients aged 12 and older, and is currently under regulatory review in additional regions. The company is advancing several other product candidates, including BCX9930, an oral Factor D inhibitor for complement-mediated diseases; BCX9250, an ALK-2 inhibitor for fibrodysplasia ossificans progressiva; and Galidesivir, an RNA-dependent RNA polymerase inhibitor aimed at treating various RNA viruses. Founded in 1986 and headquartered in Durham, North Carolina, BioCryst engages in collaborations with various institutions and organizations to enhance its research and development efforts across infectious and inflammatory diseases.

ArisGlobal LLC is a leading developer of cloud-based software solutions tailored for the life sciences industry, headquartered in Stamford, Connecticut. Founded in 1987, the company offers a comprehensive platform known as LifeSphere, which enhances the research and development process by integrating functionalities across pharmacovigilance, regulatory affairs, clinical operations, and medical information. LifeSphere encompasses a suite of tools designed to automate core functions such as case management, compliance, and reporting, enabling life sciences organizations to accelerate product development and improve safety outcomes. ArisGlobal serves over 250 clients, including biopharmaceutical companies, contract research organizations, and government health authorities, with an emphasis on streamlining collaboration among cross-functional teams. The company maintains regional offices in multiple locations worldwide, including Europe, India, Japan, and China, reinforcing its position as a global market leader in life sciences software solutions.

Secura Bio is an integrated biopharmaceutical company founded in 2019 and headquartered in Las Vegas, Nevada, with additional operations in San Diego. The company is dedicated to developing and commercializing innovative therapies, particularly in the oncology sector, to provide patients with access to life-changing treatments. By focusing on significant oncology therapies, Secura Bio aims to enhance the ability of healthcare providers to diagnose and treat serious illnesses, ultimately improving patient outcomes.

Recro Pharma is a clinical-stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting. The company's lead product, an intranasal formulation of Dexmedetomidine, or Dex, has completed a Phase Ib placebo-controlled trial demonstrating pain relief. It was founded in 2007 and headquartered in Malvern, Pennsylvania.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company based in South San Francisco, California, specializing in the development and commercialization of innovative therapeutics for thrombosis, hematologic disorders, and inflammation. Founded in 2003, Portola's lead product, Andexxa, serves as an antidote for patients treated with rivaroxaban and apixaban. The company's portfolio also includes Bevyxxa, an oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical illnesses. Additionally, Portola is developing investigational therapies such as cerdulatinib, a dual inhibitor targeting spleen tyrosine kinase and Janus kinases for hematologic cancers, and various Syk inhibitors for chronic inflammatory diseases. Portola collaborates with several major pharmaceutical companies to enhance its research and development efforts. As of July 2020, Portola operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Dermira, Inc. is a biopharmaceutical company that specializes in developing and commercializing therapies for dermatologic diseases, primarily targeting the U.S. market. Founded in 2010 and headquartered in Menlo Park, California, Dermira offers QBREXZA, a topical treatment for primary axillary hyperhidrosis in patients aged nine and older. The company is also advancing its pipeline with lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, alongside several other early-stage research initiatives in dermatology. Dermira has established strategic partnerships for the development and commercialization of its products, including agreements with Maruho Co., Ltd., F. Hoffmann-La Roche Ltd, Genentech, Inc., and UCB Pharma S.A. Notably, Dermira was previously known as Skintelligence, Inc. before rebranding in September 2011. As of early 2020, Dermira operates as a subsidiary of Eli Lilly and Company.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Agendia, Inc., established in 2003 and headquartered in Irvine, California, specializes in developing and distributing genomic-based diagnostic kits for cancer patients. The company's molecular diagnostic technology analyzes the complete human genome to provide physicians with crucial information about a patient's cancer, enabling personalized treatment plans. Agendia's breast cancer tests, for instance, help assess individual risk for metastasis and guide decisions on chemotherapy, hormonal therapy, or alternative treatments, thereby improving patient outcomes and reducing healthcare costs.

Sound Physicians is a healthcare company focused on enhancing the quality of inpatient care through its network of over 1,000 hospitalist and post-acute physicians. The company partners with more than 70 hospitals and an increasing number of post-acute care centers across the United States. It provides a range of services that span the acute episode of care, including emergency medicine, critical care, hospital medicine, population health, telemedicine, and physician advisory services. By offering these comprehensive solutions, Sound Physicians aims to improve patient satisfaction and financial performance for its hospital partners, ultimately driving better outcomes in healthcare delivery.

Water's Edge Dermatology provides medical treatments that include reconstructive surgery, skin cancer treatment, thread lifting, laser treatments, body contouring, mohs surgery, plastic surgery, dry skin conditions, facial skin conditions, hair and nail disorders, and sexually transmitted diseases.

Veloxis Pharmaceuticals A/S is a specialty pharmaceutical company dedicated to improving the lives of transplant patients through the development and commercialization of targeted medications. The company focuses on Envarsus XR, a once-daily tacrolimus tablet designed to prevent organ rejection in kidney transplant recipients. Envarsus XR has demonstrated non-inferiority to the market-leading immunosuppressant, Prograf, in key clinical trials. Veloxis employs its proprietary MeltDose technology to enhance the absorption and bioavailability of orally administered drugs, which has been validated through clinical studies and is also used in the formulation of Envarsus. Founded in 2002 as a spin-off from H. Lundbeck A/S, Veloxis is headquartered in Copenhagen, Denmark, and operates a subsidiary in the United States. The company has received regulatory approvals for Envarsus XR in both the European Union and the United States, underscoring its commitment to addressing the needs of transplant patients.

VillageMD is a healthcare management services company focused on supporting primary care physicians. Founded in 2013 and headquartered in Chicago, Illinois, the company provides a comprehensive platform that includes tools, technology, operations, and staffing support. It collaborates with physician groups, independent practice associations, and health systems to enhance quality of care, improve patient experiences, and reduce costs. VillageMD's services encompass management, clinical innovation, analytics, and value-based contract negotiation, enabling healthcare providers to achieve better clinical outcomes across various populations. The company operates in multiple markets, including Chicago, Georgia, Houston, Indianapolis, Kentucky, Michigan, New Hampshire, and Austin.

OptiNose, Inc., established in 2010 and headquartered in Yardley, Pennsylvania, is a specialty pharmaceutical company specializing in nasal drug delivery technologies and therapies. The company's proprietary Bi-Directional Delivery system enables more efficient drug deposition in the upper posterior regions of the nasal cavity, unlike traditional devices. OptiNose's flagship product, XHANCE, utilizes this technology to deliver a topically-acting corticosteroid for treating chronic rhinosinusitis with and without nasal polyps. The company is also developing OPN-300 for rare genetic obesity and autism spectrum disorder treatments, and has licensing agreements for Onzetra Xsail and orexin receptor-related products. OptiNose has offices in Norway and the UK, focusing on improving drug delivery, onset of action, efficacy, and reducing side effects.

Recro Pharma is a clinical-stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting. The company's lead product, an intranasal formulation of Dexmedetomidine, or Dex, has completed a Phase Ib placebo-controlled trial demonstrating pain relief. It was founded in 2007 and headquartered in Malvern, Pennsylvania.

Biora Therapeutics is a biotechnology company focused on developing innovative oral biotherapeutics that combine drug and device technologies. The company's primary aim is to enhance treatment approaches for patients by enabling targeted delivery of therapeutics directly to the gastrointestinal tract, particularly for conditions such as Inflammatory Bowel Disease (IBD). Additionally, Biora Therapeutics is working on systemic delivery methods that replace traditional injection techniques with needle-free, oral delivery systems. By advancing these biotherapeutic solutions, Biora Therapeutics seeks to improve patient outcomes and streamline the administration of medications, making treatments more accessible and effective.

Pharmaceutics International, Inc. is a contract development and manufacturing company that specializes in dosage form development and cGMP manufacturing services for the biotech and specialty pharmaceutical sectors both in the United States and internationally. Founded in 1994 and based in Hunt Valley, Maryland, the company produces a diverse array of dosage forms, including conventional and controlled-release tablets, soft gels, and sterile injectable products, among others. In addition to manufacturing, Pharmaceutics International offers a comprehensive suite of services such as pre-formulation, formulation, clinical trial materials manufacturing, and clinical packaging and labeling. The company is dedicated to enhancing drug quality through innovative technologies and scientific expertise, while also providing regulatory and project management support to its clients.

Medicrea is a specialized spinal implant company committed to delivering innovative technologies aimed at improving patient outcomes in spinal surgery. With over 18 years of experience, the company designs, develops, and manufactures a comprehensive range of patented products. Its offerings include personalized analytical services and implant systems, such as the UNiD Adaptive Spine Intelligence technology, as well as various spinal implant ranges, including the PASS Range, Cervical Range, and TH-LUMBAR Range. These products are intended to provide long-lasting pain relief and enhance the effectiveness of medical professionals in treating spinal conditions.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, focused on the development and commercialization of innovative medicines for iron deficiency, nephrology, and cardio-renal conditions. Incorporated in 2007, Relypsa specializes in non-absorbed polymeric drugs, aiming to address medical needs in these therapeutic areas. Its flagship product, VELTASSA, is a potassium binder used in the treatment of hyperkalemia, a condition characterized by elevated potassium levels in the blood. The company targets overlooked and undertreated conditions that can be managed through gastrointestinal applications. As of late 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

Halozyme Therapeutics, Inc. is a biotechnology company based in San Diego, California, specializing in the development and commercialization of innovative therapies that target the extracellular matrix, particularly through its proprietary ENHANZE drug delivery technology. This technology utilizes a patented recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of various injectable biologics and small molecules. Halozyme’s product portfolio includes Hylenex recombinant, which aids in fluid administration and enhances the absorption of injected drugs. The company is advancing a range of product candidates for conditions such as breast cancer, non-Hodgkin lymphoma, multiple sclerosis, and various autoimmune diseases. Additionally, Halozyme collaborates with major pharmaceutical companies to integrate its technology into therapeutic biologics. The company was founded in 1998 and operates internationally, primarily in the United States and Switzerland.

Clover Health Inc. is a health insurance company that specializes in providing Medicare Advantage plans primarily for senior citizens. Founded in 2014 and headquartered in San Francisco, California, the company operates in several states, including New Jersey, Arizona, Georgia, Pennsylvania, South Carolina, Tennessee, and Texas. Clover Health utilizes a Preferred Provider Organization (PPO) platform to enhance the quality of life for its members and their healthcare providers. The company employs patient-centered analytics and a dedicated care management team to identify potential health risks and deliver preventive care, thereby aiming to minimize avoidable spending and manage chronic diseases. Its proprietary software platform, Clover Assistant, offers personalized insights to physicians, supporting early detection and effective management of chronic conditions. Clover Health generates the majority of its revenue from its insurance segment, which includes both PPO and HMO plans.

Clover Health Inc. is a health insurance company that specializes in providing Medicare Advantage plans primarily for senior citizens. Founded in 2014 and headquartered in San Francisco, California, the company operates in several states, including New Jersey, Arizona, Georgia, Pennsylvania, South Carolina, Tennessee, and Texas. Clover Health utilizes a Preferred Provider Organization (PPO) platform to enhance the quality of life for its members and their healthcare providers. The company employs patient-centered analytics and a dedicated care management team to identify potential health risks and deliver preventive care, thereby aiming to minimize avoidable spending and manage chronic diseases. Its proprietary software platform, Clover Assistant, offers personalized insights to physicians, supporting early detection and effective management of chronic conditions. Clover Health generates the majority of its revenue from its insurance segment, which includes both PPO and HMO plans.

Apollo Endosurgery, Inc. is a medical technology company based in Austin, Texas, specializing in the design, development, and commercialization of innovative medical devices for gastrointestinal health. Founded in 2005, the company focuses on advancing therapeutic endoscopy as a less invasive alternative to traditional surgical procedures, thereby reducing complication rates and overall healthcare costs. Its product portfolio includes the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which enable physicians to place full-thickness sutures and secure tissue approximation through flexible endoscopy. Additionally, Apollo offers the X-Tack Endoscopic HeliX Tacking System and the Orbera Intragastric Balloon, which aids in weight management by reducing stomach capacity. The company's devices cater to gastroenterologists and bariatric surgeons, addressing various gastrointestinal conditions such as acute perforations and chronic fistulas. Apollo Endosurgery's commitment to innovation is rooted in the collaborative efforts of a distinguished group of gastroenterologists and surgeons who aimed to enhance the field of therapeutic endoscopy.

Zealand Pharma A/S is a biotechnology company based in Copenhagen, Denmark, specializing in the discovery and development of peptide-based medicines. The company has a growing proprietary pipeline that includes several clinical candidates such as glepaglutide for short bowel syndrome and dasiglucagon for diabetes management and congenital hyperinsulinism. Zealand's first developed medicine, lixisenatide, is a once-daily GLP-1 analogue for Type 2 diabetes, marketed globally outside the US. The company has established collaborations with major pharmaceutical partners, including Sanofi, Helsinn Healthcare, and Boehringer Ingelheim, enhancing its product offerings and expanding its reach in the market. Zealand Pharma is committed to advancing innovative therapies, with multiple projects in various stages of clinical development and preclinical research.

Travere Therapeutics, Inc. is a biopharmaceutical company dedicated to the identification, development, and commercialization of therapies for rare diseases, particularly in the fields of nephrology, hepatology, and metabolism. The company markets several products, including Chenodal for the treatment of gallbladder stones, Cholbam for bile acid synthesis disorders, and Thiola for cystinuria. Its key pipeline candidate, Sparsentan, is in Phase III clinical trials for focal segmental glomerulosclerosis and immunoglobulin A nephropathy, both serious kidney conditions. Additionally, Travere sponsors no-cost genetic testing to aid in the diagnosis of cholestasis in children and collaborates with patient advocacy organizations to support the needs of patients and their families. Founded in 2011 and headquartered in San Diego, California, Travere Therapeutics was previously known as Retrophin, Inc., adopting its current name in November 2020.

Travere Therapeutics, Inc. is a biopharmaceutical company dedicated to the identification, development, and commercialization of therapies for rare diseases, particularly in the fields of nephrology, hepatology, and metabolism. The company markets several products, including Chenodal for the treatment of gallbladder stones, Cholbam for bile acid synthesis disorders, and Thiola for cystinuria. Its key pipeline candidate, Sparsentan, is in Phase III clinical trials for focal segmental glomerulosclerosis and immunoglobulin A nephropathy, both serious kidney conditions. Additionally, Travere sponsors no-cost genetic testing to aid in the diagnosis of cholestasis in children and collaborates with patient advocacy organizations to support the needs of patients and their families. Founded in 2011 and headquartered in San Diego, California, Travere Therapeutics was previously known as Retrophin, Inc., adopting its current name in November 2020.

Pernix Therapeutics is a specialty pharmaceutical company dedicated to the development, marketing, and sale of branded and generic medications, primarily targeting the pediatric market. Its product offerings aim to enhance children's health and well-being, focusing on areas such as allergies, upper respiratory conditions, antibiotics, and dermatology issues like head lice and contact dermatitis. The company employs a sales and marketing team of approximately 55 representatives who concentrate their efforts in densely populated states, engaging pediatricians and high-prescribing physicians to promote their products. Pernix's current strategy emphasizes maximizing sales from its existing portfolio while also planning for future growth through the introduction of new products, line extensions, and formulations, as well as acquiring and licensing approved products.

SynCardia Systems, Inc. is a medical technology company based in Tucson, Arizona, founded in 2001. The company specializes in the development, manufacturing, and commercialization of the SynCardia temporary Total Artificial Heart (TAH-t), an implantable device designed to fully replace the function of a failing heart in patients with advanced heart failure. The SynCardia TAH-t serves as a critical bridge to transplant, enabling patients to survive while awaiting a matching donor heart. SynCardia operates in the United States, European Union, and Canada, focusing on improving outcomes for individuals with severe cardiac conditions.

InnoPharma, LLC, founded in 2005 and located in Piscataway, New Jersey, is a privately held pharmaceutical research and development company. The firm specializes in developing complex generic and innovative specialty pharmaceutical and bio-pharmaceutical products, particularly in injectable and ophthalmic dosage forms. InnoPharma boasts a diverse portfolio of products in various stages of development, utilizing advanced formulations such as suspensions, lyophilized products, emulsions, liposomes, micelles, and lipid complexes.

TRIA Beauty, Inc. is a developer and marketer of light-based medical devices aimed at the consumer market, specializing in beauty and skincare solutions. Founded in 2003 and headquartered in Dublin, California, the company offers a range of innovative products including a hand-held, cordless diode laser for hair removal, a Skin Perfecting Blue Light device for acne treatment, a Skin Rejuvenating Laser for anti-aging purposes, and an Age-Defying Eye Wrinkle Correcting Laser. These devices utilize advanced light technology, which is preferred by dermatologists for effective skincare treatments, allowing users to achieve professional results at home. TRIA Beauty products are available through its e-commerce platform and various indirect sales channels, including retail outlets, television, and physician offices. The company serves a global market, reaching customers in the United States, Japan, South Korea, Canada, the United Kingdom, Germany, and Spain.

TRIA Beauty, Inc. is a developer and marketer of light-based medical devices aimed at the consumer market, specializing in beauty and skincare solutions. Founded in 2003 and headquartered in Dublin, California, the company offers a range of innovative products including a hand-held, cordless diode laser for hair removal, a Skin Perfecting Blue Light device for acne treatment, a Skin Rejuvenating Laser for anti-aging purposes, and an Age-Defying Eye Wrinkle Correcting Laser. These devices utilize advanced light technology, which is preferred by dermatologists for effective skincare treatments, allowing users to achieve professional results at home. TRIA Beauty products are available through its e-commerce platform and various indirect sales channels, including retail outlets, television, and physician offices. The company serves a global market, reaching customers in the United States, Japan, South Korea, Canada, the United Kingdom, Germany, and Spain.

BioFire Diagnostics is a clinical diagnostics company based in Salt Lake City, Utah, that focuses on detecting pathogens and mutations for molecular diagnostics. Founded in 1990, the company holds over 70 patents related to polymerase chain reaction (PCR) technology, including innovations in rapid PCR cycling. BioFire offers nearly 200 products tailored for clinical, research, and military applications. Its services are designed to provide accurate results in syndromic infectious disease diagnostics, utilizing real-time thermocycling and mutation scanning. BioFire's diagnostic panels test for a wide range of viruses, bacteria, and antimicrobial resistance genes, thereby enabling healthcare providers to assess and improve treatment outcomes for patients of all ages.

SynCardia Systems, Inc. is a medical technology company based in Tucson, Arizona, founded in 2001. The company specializes in the development, manufacturing, and commercialization of the SynCardia temporary Total Artificial Heart (TAH-t), an implantable device designed to fully replace the function of a failing heart in patients with advanced heart failure. The SynCardia TAH-t serves as a critical bridge to transplant, enabling patients to survive while awaiting a matching donor heart. SynCardia operates in the United States, European Union, and Canada, focusing on improving outcomes for individuals with severe cardiac conditions.

Verenium possesses integrated, end-to-end capabilities in pre-treatment, novel enzyme development, fermentation, engineering, and project development and is moving rapidly to commercialize its proprietary technology for the production of cellulosic ethanol from a wide array of feedstocks, including sugarcane bagasse, dedicated energy crops, agricultural waste, and wood products. In addition to the vast potential for advanced biofuels, a multitude of large-scale industrial opportunities exist for the Company for products derived from the production of low-cost, biomass-derived sugars.

BioFire Diagnostics is a clinical diagnostics company based in Salt Lake City, Utah, that focuses on detecting pathogens and mutations for molecular diagnostics. Founded in 1990, the company holds over 70 patents related to polymerase chain reaction (PCR) technology, including innovations in rapid PCR cycling. BioFire offers nearly 200 products tailored for clinical, research, and military applications. Its services are designed to provide accurate results in syndromic infectious disease diagnostics, utilizing real-time thermocycling and mutation scanning. BioFire's diagnostic panels test for a wide range of viruses, bacteria, and antimicrobial resistance genes, thereby enabling healthcare providers to assess and improve treatment outcomes for patients of all ages.